RxDoctor Payments Data

Robert Brownlee, MD

Internal Medicine · Charlotte, NCNPI 1528379609

Payments from drug & device makers

$1,424in general payments, 2019–2025

Across 76 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$345
  • AbbVie$276
  • Abbott$198
  • Novo Nordisk$144
  • Amgen$120
  • Gilead$92
  • plus $249 from 10 others

What the payments were for

  • Food & beverage$1,424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,424 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$137,562
Medicare patients
339
Services billed
2,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$100,235
OzempicSemaglutide46$60,597
MounjaroTirzepatide43$44,766
XareltoRivaroxaban15$22,981
MyrbetriqMirabegron33$19,044
JardianceEmpagliflozin17$17,299
AuvelityDextromethorphan Hbr/Bupropion12$14,870
Breo ElliptaFluticasone/Vilanterol13$7,243
JanuviaSitagliptin Phosphate12$6,919
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$5,014
PaxlovidNirmatrelvir/Ritonavir27$4,288
Atorvastatin Calcium432$3,838
Incruse ElliptaUmeclidinium Bromide12$3,540
Rosuvastatin Calcium369$3,251
Duloxetine Hcl53$2,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$33$104,523127 claims
Novo NordiskOzempic$144$60,59746 claims
Lilly USA, LLCMounjaro$38$44,76643 claims
Boehringer IngelheimJardiance$17$17,29917 claims
GSKBreo Ellipta, Incruse Ellipta$345$10,78325 claims
AbbVieSynthroid$276$2,72726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →